Evidence from the Enara model
Conference posters and clinical research from our team and partners on hybrid obesity care, outcomes, and cardiometabolic health.
Hybrid Obesity Care Reduces Inflammation at 12 Months in Adults With Obesity
Both AOM and non-AOM participants showed reduced systemic inflammation at 12 months, with hsCRP reductions of -1.22 mg/L and -2.10 mg/L respectively. No significant between-group differences were found, suggesting the hybrid program itself is associated with inflammatory improvement.
Obesity Medicine Certification Enhances GLP-1 Receptor Agonist Outcomes Through 18 Months: A Real-World Multi-Site Cohort Study
Among 1,449 patients receiving GLP-1 RA therapy, those attributed to obesity-certified providers achieved 2.3 percentage points greater weight loss at 6 months than those attributed to non-certified providers, an advantage that grew to 3.1 points at 12 months and was sustained at 2.6 points at 18 months.
Real-World Weight Outcomes With Tirzepatide and Semaglutide in an Integrated Obesity Care Program
Among 1,086 adults in an integrated obesity care program, early tirzepatide (≤60 days) achieved −15.2% weight loss at 12 months vs. −10.4% for early semaglutide — but visit engagement, not drug choice, was the most consistent driver of outcomes.
A Digital Cardiology-Embedded Obesity Platform Produces Sustained Clinical and Financial Outcomes, Redefining Cardiovascular Prevention
Over 70% of patients maintained at least 10% weight loss at 18 months, with more than 40% achieving 15% loss, alongside meaningful improvements in blood pressure, cholesterol, and HbA1c. The model also generates $311 per patient per month, creating a new revenue stream for practices.
Care Factors Associated With Sustained 15% Weight Loss at Three Years in Patients Not Taking AOMs
1 in 5 Enara patients lost over 15% of their weight at 3 years - with no medications. Consistent, digital-first engagement set the high achievers apart.
Impact of Medicaid vs Commercial Insurance Status on Weight Loss Outcomes With and Without AOMs
Even when motivation is the same, access isn't. This study shows that Medicaid patients can achieve outcomes comparable to commercially insured peers when given access to anti-obesity medications.
Beyond Weight Loss Percent: Key Factors Associated With SMM Preservation in an Obesity Care Program
Not all weight loss is good weight loss. High achievers preserved skeletal muscle mass while losing fat - and the difference came from dietary and pharmacological intensity, not exercise volume.